Massoud Fadi
Hôpital Notre-Dame, Service de gériatrie, 1560, Sherbrooke Est, Montréal, (Québec) H2L 2M1.
Can Fam Physician. 2007 Jan;53(1):50-4.
Alzheimer disease (AD) is the most common form of dementia. There have been many advances in the pharmacological treatment of AD in recent years. This article discusses 2 of these advances: vascular prevention and a new molecule, memantine.
The conclusions and recommendations in this article are based on data from studies providing level I and level II evidence.
Recent data suggest that vascular disease plays an important role in the physiopathology of AD. Memantine is a non-competitive, low-affinity N-methyl-D-aspartate receptor antagonist of glutamate that offers a very attractive efficacy and safety profile for treating moderate to severe AD.
The prevention and treatment of vascular risk factors should be an integral part of the management of AD. For the treatment of moderate to severe AD, memantine is a new option that is effective and well tolerated.
阿尔茨海默病（AD）是最常见的痴呆形式。近年来，AD的药物治疗取得了许多进展。本文讨论其中两项进展：血管预防和一种新分子——美金刚。
本文的结论和建议基于提供I级和II级证据的研究数据。
近期数据表明，血管疾病在AD的病理生理过程中起重要作用。美金刚是一种非竞争性、低亲和力的谷氨酸N-甲基-D-天冬氨酸受体拮抗剂，在治疗中度至重度AD方面具有非常有吸引力的疗效和安全性。
血管危险因素的预防和治疗应成为AD管理的一个组成部分。对于中度至重度AD的治疗，美金刚是一种有效且耐受性良好的新选择。
